
Psoriasis
Latest News

Latest Videos

Shorts




More News

The Emerging Role of Oral Peptide Therapeutics in Psoriasis and Beyond
Oral peptide pills are reshaping psoriasis care, from semaglutide breakthroughs to IL‑23 blocker icotrokinra—here's what dermatologists need to know now.

Review 10 evidence-based answers on GPP pathophysiology, diagnosis, and IL-36-targeted management, drawn from National Psoriasis Foundation consensus and emergency medicine literature.

Envudeucitinib achieved PASI 100 in 54% of continuously treated patients at 48 weeks in the phase 3 ONWARD3 extension study.

Sonelokimab met the primary end point in phase 3 IZAR-1, with 42.1% of biologic-naive patients achieving ACR50 at week 16.

New oral TYK2 inhibitor shows rapid PASI 75/90 skin clearance in phase 2 plaque psoriasis study, with encouraging safety.

Obesity may blunt biologic psoriasis gains, according to a 4,200‑patient meta‑analysis showing lower PASI responses, but weight alone shouldn’t drive drug choice.

NPF guidance outlines patient selection, counseling, and multidisciplinary management of GLP-1 receptor agonists in psoriasis.

Philip J. Mease, MD, reviews guselkumab's mechanism of action and its expanded FDA-approved indication for psoriatic arthritis joint damage inhibition.

Recapping 5 practice-changing FDA decisions from the first half of 2026, including icotrokinra, expanded pediatric indications, and more!

A recent JAAD study identified a dual Th17/Type 2 immune signature in psoriasis that may help explain why biologic responses vary among patients.

New case-control data link smoking to higher nail psoriasis severity, urging screening and cessation to ease nail symptoms and boost quality of life.

Can-Fite completed interim enrollment for its pivotal phase 3 trial of first-in-class oral A3AR agonist piclidenoson, a potential new mechanism for plaque psoriasis.

Linda Stein Gold, MD, discusses zasocitinib's safety and efficacy as an oral treatment for plaque psoriasis.

Linda Stein Gold, MD, reviews the recent LATITUDE Atlas head-to-head trial results showing zasocitinib's superiority over deucravacitinib for plaque psoriasis.

Christopher Bunick, MD, PhD, discusses the FDA's expanded approval of roflumilast cream 0.3% for plaque psoriasis in children as young as 2 years of age.














